The COL6A2 gene helps make collagen VI, a support protein that gives strength and flexibility to muscles, skin, and other connective tissues. If it does not work properly, connective tissue is less stable, which can lead to muscle weakness, tight joints, loose joints, and breathing problems in some people. Pathogenic variants in this gene are linked to collagen VI related muscle conditions, including Bethlem myopathy and Ullrich congenital muscular dystrophy.
What is a gene?
A gene is a stretch of DNA that carries instructions your cells use to make molecules or manage processes throughout the body. Some genes provide the directions for producing proteins, which are the parts of cells that do much of the work. Others mainly regulate when certain processes happen, where they happen, and how active they are. Taken together, genes affect how the body grows and works, and they can influence how you respond to food, stress, or medications. To go further into this topic, you can find more in the LearnHub.
Overview
COL6A2Gene function
What if the gene works
The COL6A2 gene helps make type VI collagen, a protein that supports the body's connective tissues. This collagen forms a fine mesh around muscle cells, skin, and tendons, helping tissues stay strong and flexible.
Risk
What if the gene does not work
Variants in the COL6A2 gene can cause collagen VI related muscle conditions, from milder Bethlem myopathy to more severe Ullrich congenital muscular dystrophy. Different variants can change onset and severity, with muscle weakness, joint looseness or stiffness, sometimes breathing problems.
Treatment
What does that mean for your treatment
No treatment tailored to pathogenic variants in the COL6A2 gene is currently established, so drug choices are not guided by this gene in routine care. Research is exploring collagen VI targeted and gene based therapies, but these approaches remain early stage.
Conditions associated with COL6A2
Gene function
What if the gene works
Your muscles and other connective tissues need a supportive mesh around each cell. The COL6A2 gene helps make one piece of collagen VI, a protein that forms this mesh in muscle, skin, tendons, and similar tissues. Understanding the COL6A2 gene function in connective tissue helps show how your body stays flexible while still holding cells in place.
The COL6A2 gene provides instructions for one chain of collagen VI, called the alpha 2 chain. This chain joins matching partners so your cells can assemble the full collagen VI protein.
Collagen VI forms a fine net in the extracellular matrix (the supportive material around cells). It creates a steady space where cells can sit, move, and handle everyday pull and pressure.
This protein helps cells attach to nearby support fibers and other matrix parts. That connection helps tissues stay organized and share force more evenly.
In muscle, skin, and tendons, collagen VI adds gentle strength while allowing stretch. It supports normal movement and everyday wear from walking, lifting, and reaching.
What is a variant?
A genetic variant is a small difference in the DNA sequence of a gene. These differences are common and help shape normal human diversity, including variation in appearance, metabolism, or how the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant changes how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the COL6A2 gene can change the shape or amount of the collagen VI alpha-2 chain, so the protein may fold poorly, fail to join its partner chains, or be released less effectively outside the cell. Some COL6A2 gene variants have a mild effect and leave partial collagen VI function, while more disruptive variants can strongly interfere with collagen VI assembly and stability. This range often matches a later, milder course or earlier, more marked collagen VI-related muscle weakness and joint changes.
How variants are linked to conditions
Certain variants in the COL6A2 gene cause collagen VI-related dystrophy, a group of inherited muscle conditions. These include Bethlem muscular dystrophy and Ullrich congenital muscular dystrophy, and some people fall between these two ends of the spectrum. COL6A2 gene variants linked to Bethlem muscular dystrophy or Ullrich congenital muscular dystrophy can affect muscle strength, joint movement, and sometimes breathing over time.
A variant is not necessarily a diagnosis
Genetic variants are common across the general population and are a normal feature of human biology. Most do not directly affect health and simply reflect natural variation among people. For many genes, having a variant associated with a condition points to a possible link rather than a certain diagnosis, particularly when several genes and environmental influences play a role. In some situations, though, one well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
Risk is mainly shaped by whether a harmful COL6A2 variant is present, often because it runs in a family or starts for the first time in a child. Specific lifestyle or environmental factors that clearly increase or reduce COL6A2-related risk have not been broadly confirmed.
Inheritance of COL6A2 variants
How COL6A2 gene variants are inherited depends on the specific collagen VI related muscle condition involved. Some COL6A2 related conditions follow an autosomal dominant pattern, which means a parent carrying the variant can pass it to a child with a 50% chance in each pregnancy. Others follow an autosomal recessive pattern, which means a child usually inherits one altered copy from each parent, and carrier parents are often unaffected. Because of this, the COL6A2 inheritance pattern is not the same for every family.
What does my COL6A2 result mean for my family?
For COL6A2, what it means for family members depends on the exact condition and variant, because this gene can be linked to both dominant and recessive muscle conditions. In dominant families, close relatives such as a parent, brother, sister, or child may also carry the variant; some dominant cases happen as a new change, so a parent is not always the source. In recessive families, parents are often healthy carriers, and brothers or sisters may also be carriers or affected.
Genetic information
Genetic testing
How you find out about variants
To look for changes linked with collagen VI related conditions, COL6A2 genetic testing usually analyzes a blood or saliva sample by reading the DNA code of the COL6A2 gene. Results may identify a pathogenic variant, a benign variant, or a variant of uncertain significance, which means the change has not yet been clearly linked to health effects.
When should I consider getting a genetic test?
Genetic testing for the COL6A2 gene may be worth considering if you or your child has ongoing muscle weakness, joint stiffness or unusual looseness, delayed walking, or a family history of Bethlem muscular dystrophy or Ullrich congenital muscular dystrophy. It can help show whether a change in COL6A2 is the cause.
A genetic result is only one part of your health story
How much a genetic result can tell you varies by the condition and the kind of variant involved, even though it can offer meaningful insight. Factors such as lifestyle, environment, age, and medical history all influence how the body works over time. For some conditions, particularly those shaped by many genes, genetic information provides context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result can give a clear answer. In areas like medication response, genetic results may also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the body, or responds to it at its target. This helps explain why the same treatment may work well for one person, seem less effective for another, or cause more side effects in someone who is more sensitive to it.
What is Pharmacogenetics?
Pharmacogenetics examines how inherited genetic differences shape the way people respond to medicines. It studies gene and drug patterns to help explain why the same treatment can affect one person differently than another. For many drugs, genes can influence both how the body handles the medication and how strong its effects are. This information can support more informed, more personalized treatment choices. More detail on this topic is available in the LearnHub.
Drugs influenced by the COL6A2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding how medicines are chosen or adjusted. If you have medication side effects, new symptoms, or concerns about how treatment is affecting you, it is best to discuss them with your doctor.
History
Throughout history, people described families with mild to moderate muscle weakness and joint stiffness long before the genetic cause was clear. Initially understood only through visible traits, later recognized as tied to a specific gene, these patterns helped guide research on collagen VI related conditions. In the 1990s, studies linked variants in the COL6A2 gene to Bethlem myopathy, a key step in showing that some inherited muscle conditions arise from changes in collagen VI genes. Building on this early work, scientists also connected collagen VI gene variants, including changes in the COL6A2 gene, with Ullrich congenital muscular dystrophy, broadening the clinical picture. These historical steps shaped today’s understanding of how different collagen VI related conditions can overlap within the same gene family.